These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19465330)

  • 41. Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience.
    Anderson JF; Swanson DA; Levy LB; Kuban DA; Lee AK; Kudchadker R; Phan J; Bruno T; Frank SJ
    Urology; 2009 Sep; 74(3):601-5. PubMed ID: 19589580
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Physical and emotional predictors of depression after radical prostatectomy.
    Weber BA; Roberts BL; Mills TL; Chumbler NR; Algood CB
    Am J Mens Health; 2008 Jun; 2(2):165-71. PubMed ID: 19477780
    [TBL] [Abstract][Full Text] [Related]  

  • 43. United States military contributions to the National Cancer Institute.
    Sarvis JA; Thompson IM
    Urol Oncol; 2009; 27(5):558-61. PubMed ID: 19720303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Guideline for 5-alpha-reductase inhibitors in the prevention of prostate cancer is premature.
    Frankel PH; Twardowski P
    J Clin Oncol; 2009 Oct; 27(30):e164; author reply e165. PubMed ID: 19738114
    [No Abstract]   [Full Text] [Related]  

  • 45. Prospective evaluation of prostate cancer risk in candidates for inguinal hernia repair.
    Thomas AA; Rosenblatt S; Wachterman J; Liao W; Moussa A; Ponsky LE; Jones JS
    J Am Coll Surg; 2009 Sep; 209(3):371-6. PubMed ID: 19717042
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The risk and prophylactic management of bladder cancer after various forms of radiotherapy.
    Shirodkar SP; Kishore TA; Soloway MS
    Curr Opin Urol; 2009 Sep; 19(5):500-3. PubMed ID: 19553822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of cancer screening services in Greece and associated social factors: results from the nation-wide Hellas Health I survey.
    Dimitrakaki C; Boulamatsis D; Mariolis A; Kontodimopoulos N; Niakas D; Tountas Y
    Eur J Cancer Prev; 2009 Jun; 18(3):248-57. PubMed ID: 19491613
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Decrease in prostate cancer incidence and mortality in Germany - effects of opportunistic PSA screening or more?
    Rohde V; Weidner W; Katalinic A
    Urol Int; 2009; 83(2):134-40. PubMed ID: 19752605
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The thunder of hooves in a tunnel.
    Czap A
    Altern Med Rev; 2002 Apr; 7(2):93. PubMed ID: 11991789
    [No Abstract]   [Full Text] [Related]  

  • 50. Duplicate presentations on prostate cancer at American Urological Association and European Association of Urology annual meetings.
    Pop GH; Fesperman SF; Ball DA; Yeung LL; Vieweg J; Dahm P
    J Urol; 2009 Aug; 182(2):674-8; discussion 678-9. PubMed ID: 19535105
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A framework for the identification of men at increased risk for prostate cancer.
    Roobol MJ; Schröder FH; Crawford ED; Freedland SJ; Sartor AO; Fleshner N; Andriole GL
    J Urol; 2009 Nov; 182(5):2112-20. PubMed ID: 19758625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polymorphisms in tumor necrosis factor-A gene and prostate cancer risk in North Indian cohort.
    Kesarwani P; Mandhani A; Mittal RD
    J Urol; 2009 Dec; 182(6):2938-43. PubMed ID: 19846139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).
    Hoffman RM; Couper MP; Zikmund-Fisher BJ; Levin CA; McNaughton-Collins M; Helitzer DL; VanHoewyk J; Barry MJ
    Arch Intern Med; 2009 Sep; 169(17):1611-8. PubMed ID: 19786681
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate cancer: current evidence weighs against population screening.
    Boyle P; Brawley OW
    CA Cancer J Clin; 2009; 59(4):220-4. PubMed ID: 19564244
    [No Abstract]   [Full Text] [Related]  

  • 55. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
    Howard K; Barratt A; Mann GJ; Patel MI
    Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Epidemiology of prostatic cancer].
    Soulié M
    Prog Urol; 2003 Nov; 13(5 Suppl 2):1261. PubMed ID: 15816401
    [No Abstract]   [Full Text] [Related]  

  • 57. CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis.
    Shaik AP; Jamil K; Das P
    Urol J; 2009; 6(2):78-86. PubMed ID: 19472123
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PSA testing in Austria: induced morbidity and saved mortality.
    Vutuc C; Waldhoer T; Lunglmayr G; Hoeltl W; Haidinger G
    Eur J Cancer Prev; 2009 Sep; 18(5):377-80. PubMed ID: 19512934
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Introduction.
    Lieberman R; Nelson WG
    Urology; 2001 Apr; 57(4 Suppl 1):1-3. PubMed ID: 11295589
    [No Abstract]   [Full Text] [Related]  

  • 60. [44th Congress of the French Society of Stomatology and Maxillofacial Surgery, Rouen, 2-5 July 2008].
    Sabin P
    Rev Stomatol Chir Maxillofac; 2008 Jun; 109(3):133-5. PubMed ID: 18533214
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.